Eversept Partners LP Makes New $1.03 Million Investment in Savara Inc. $SVRA

Eversept Partners LP acquired a new position in Savara Inc. (NASDAQ:SVRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 170,195 shares of the company’s stock, valued at approximately $1,026,000. Eversept Partners LP owned about 0.08% of Savara at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SVRA. Osaic Holdings Inc. increased its holdings in shares of Savara by 6.9% during the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after purchasing an additional 2,098 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Savara by 3.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after acquiring an additional 2,116 shares during the period. Graham Capital Management L.P. raised its holdings in Savara by 4.9% in the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after acquiring an additional 2,615 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Savara by 9.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock worth $200,000 after acquiring an additional 2,859 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Savara by 48.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on SVRA. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company. William Blair set a $10.00 target price on shares of Savara in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and an average price target of $10.14.

Savara Stock Up 1.5%

NASDAQ SVRA opened at $5.38 on Thursday. The stock’s 50 day simple moving average is $5.27 and its 200 day simple moving average is $5.60. Savara Inc. has a one year low of $1.98 and a one year high of $7.01. The firm has a market cap of $1.10 billion, a PE ratio of -9.61 and a beta of 0.26. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, sell-side analysts forecast that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.